Board of Directors
Elias Papatheodorou, Independent Chairman
Elias Papatheodorou has over 20 years of C-level experience in all aspects of pharmaceutical commercialization, including sales & marketing, business development, M&A, and operations. He has a proven track-record of managing clinical-stage organizations and preparing them for sale. He is currently the CEO of Genkyotex, which was sold to Calliditas Therapeutics, and was previously the CBO at Covagen, which was acquired by Janssen Pharmaceuticals.
Dr. Thomas Taapken, Independent Board Member
Thomas Taapken has over 20 years of experience in the life science industry at the executive management level. His experience spans public & private financings, IPO, corporate & business development, and research. He is currently the CFO of InflaRx and has previously held various C-level positions at both private and publicly listed companies, including Medigene, Epigenomics and Biotie Therapies. He holds a PhD in Organic Chemistry from Technical University of Berlin.
Dr. Robert Schier, Swisscanto, Investor Representative
Robert Schier joined Swissanto Invest at Zürcher Kantonalbank in 2018 as Member of Senior Management, Investment Director PE/VC. He has many years' experience in the healthcare and life sciences sector with background in biotech and as investment director and/or partner in various venture capital firms, such as Inventages Venture Capital and Seventure Partners.Robert Schier holds a degree in pharmacy from the University of Vienna and a PhD in biotechnology from the University of Natural Resources and Life Sciences, Vienna. He received the Keystone Award for Excellence in Research for his outstanding doctoral thesis, which he completed at the University of California, San Francisco. Dr Schier then completed an executive MBA programme at the European University Munich and is the author of several scientific publications and patents.
Dr. Nadine Geiser, Redalpine, Investor Representative
Nadine Geiser is Investment Manager at Redalpine. She studied biotechnology in Munich and Singapore before completing a PhD at ETH Zurich. She worked in Amsterdam for M Ventures, a corporate venture firm, and in the equity research department of Vontobel, an investment bank in Zurich, before ultimately joining Redalpine.
Dr. Christoph Esslinger, CSO, Board Member
Christoph Esslinger is the CSO and scientific founder of Memo Therapeutics AG and a pioneer of the discovery of therapeutic antibody candidates directly from human donors for immunotherapy of Alzheimer’s Disease and cancer. Prior to founding Memo Therapeutics AG he held senior positions at CT Atlantic AG, Neurimmune AG and in academia. Christoph Esslinger holds a diploma in Technical Biology from University of Stuttgart and a PhD in Molecular Immunology from the Ludwig Institute for Cancer Research, Lausanne Branch and University of Lausanne.